Ranibizumab biosimilar is under clinical development by Shanghai United Cell Biotechnology and currently in Phase I for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase I drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ranibizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ranibizumab biosimilar overview

ranibizumab biosimilar is under development for the treatment of wet age-related macular degeneration (AMD), diabetic maculopathy, retinal vascular occlusion and choroidal neovascularization. It is a monoclonal antibody fragment against vascular endothelial growth factor (VEGF). The therapeutic candidate acts by targeting vascular endothelial growth factor (VEGF). It is administered through intravitreal route. It was also under development for the treatment of is diabetic maculopathy, retinal vascular occlusion and choroidal neovascularization.

Shanghai United Cell Biotechnology overview

Shanghai United Cell Biotechnology (SUCB), a subsidiary of Hillhouse Capital Group, is a biotechnology company. It carries out the research, development and commercialization of genetically recombinant biological products and vaccines. The company’s products include recombinant parathyroid hormone injection; recombinant B-subunit, a whole cell cholera vaccine; and recombinant human growth hormone injection. Its products under R&D comprise of R16 drug for pediatric and adult hormone deficiency, idiopathic short stature, turner syndrome and other diseases; R27, a liquid injection formulation to treat osteoporosis, male hypogonodiac osteoporosis and glucocorticoid-induced osteoporosis. The company is also developing R30, a monoclonal antibody fragment targeting ophthalmic diseases; and R24, a biological product to prevent helicobacter pylori infection. It operates manufacturing facility in Zhuhai High-tech Zone, China. SUCB is headquartered in Shanghai, China.

For a complete picture of Ranibizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.